A Trial to Evaluate the Safety, Local Tolerability, Pharmacokinetics and Pharmacodynamics of LDE225 on Skin Basal Cell Carcinomas in Gorlin Syndrome Patients

Clinical trial NCT00961896 · COMPLETED

Trial details

NCT number: NCT00961896
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients

Start date: 2009-07-01
Primary completion: 2010-08-01
Enrollment: 18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.